AIDS TREATMENT NEWS Issue #387, December 27, 2002
John S. James
| Topic | Issue(s) |
|---|---|
| Aaron Diamond Research Center | 384 |
| Abbreviated Guide ... HIV | 380 |
| Access to care | 387 |
| Achmat, Zackie | 387 |
| ACT UP | 385 |
| ACTG 384 trial changes | 382 |
| Activism | 377, 379, 385, 387 |
| ADAP crisis | 381, 382, 386, 387 |
| ADAP waiting list advice | 381 |
| ADAP | 380 |
| Advocacy | 387 |
| African Services Committee | 385 |
| AIDS Drug Assistance Program | (see ADAP) |
| AIDSWatch lobbying | 380 |
| Amprenavir approved | 378 |
| Anti-HIV factor | 384 |
| Atazanavir | 379 |
| Avascular necrosis | 379 |
| Barcelona conference take-home messages | 382 |
| Barcelona conference visa problems | 381 |
| Barcelona conference Web sites | 381 |
| Barcelona online reports | 382 |
| Benefits issues | 377 |
| Bone problems | 379 |
| Buyers' club list | 387 |
| Chinese activist, Dr. Wan Yanhai | 383 |
| Coca-Cola protest | 384 |
| Conferences and meetings list | 378 |
| Congress | 387 |
| Cost of international conferences | 381 |
| Counterfeit drugs | 380 |
| C-Reactive Protein | 385 |
| d4T -- side effects | 378 |
| d4T and lipoatrophy | 378 |
| Deca Durabolin availability problems | 381 |
| Defensins | 384 |
| Doctors Without Borders | 385 |
| Doha, Qatar | 386 |
| Drug interactions | 377 |
| Drug pricing | 377 |
| Efavirenz once daily | 378 |
| Epogen | 380 |
| Facial injections | 378 |
| Fundraising | 377 |
| FUZEON | (see T-20) |
| Global Fund | 379 |
| Government AIDS Web site | 386 |
| Grossman, Dr. Howard, interview | 383 |
| Guidelines on metabolic complications | 385 |
| Health GAP | 385 |
| Heart disease prevention | 377 |
| Heart disease | 385 |
| Hepatitis C | 384 |
| HIV harm reduction | 384 |
| ICAAC conference, clinical trials | 384 |
| Integrase inhibitor | 379 |
| Intellectual property | 385 |
| Intellectual property | 386 |
| Interactions of drugs | 377 |
| Johns Hopkins short guide | 380 |
| Junk foods | 377 |
| Kaiser, Jon, M.D. | 383 |
| Lactic acidosis | 378 |
| Legal issues | 377 |
| Lipoatrophy -- drug changes | 378 |
| Lipodystrophy strategies | 383 |
| Marijuana lung report | 385 |
| Marijuana | 379 |
| Measles may suppress HIV | 379 |
| Medicaid crisis | 387 |
| Medicaid funding | 380 |
| Medical privacy rules | 379 |
| Medical research funding | 377 |
| Metabolic complications -- guidelines | 385 |
| MSF (Doctors Without Borders) | 385 |
| Nandrolone availability problems | 381 |
| Nandrolone generic | 382 |
| NATAF conference | 382 |
| NDRI (National Disease Research Interchange) | 385 |
| Network of People ... Nigeria | 385 |
| Neuromuscular weakness | 378 |
| Nevirapine patient assistance program | 385 |
| New drugs at Retroviruses conference | 379 |
| Nigeria -- patent meeting | 385 |
| Nonoxynol-9 dangers | 381 |
| Nonoxynol-9 dangers | 384 |
| Once-a-day dosing | 383 |
| Oxfam | 385 |
| Patents on pharmaceuticals | 385 |
| Patents on pharmaceuticals | 386 |
| Patient assistance programs | 385 |
| Peginterferon (hepatitis C) | 384 |
| PHATAM (Pan African HIV/AIDS Treatment Access Movement) | 383 |
| Philadelphia, AIDS Education Month | 380 |
| Political organizing | 387 |
| Prevention -- tenofovir | 385 |
| Pricing of drugs | 377 |
| Protease inhibitors | 383 |
| Remune controversy | 380 |
| Resistance testing | 383 |
| Retroviruses conference | 378 |
| Retroviruses conference 387 | |
| Retroviruses conference, Web coverage | 378 |
| Ribavirin (hepatitis C) | 384 |
| S-1360 integrase inhibitor | 379 |
| Search for a Cure | 387 |
| Serostim | 380 |
| Smallpox vaccination begins | 386 |
| Smallpox vaccination questions | 387 |
| Superinfection risk | 383 |
| T-20 | 383, 384 |
| Tenofovir access in poor countries | 386 |
| Tenofovir for prevention | 385 |
| Tenofovir | 377, 383 |
| Tipranavir | 379 |
| Tissue donation | 385 |
| TMC125 | 379 |
| Topoisomerase inhibitors | 379 |
| Treatment Action Movement of Nigeria | 385 |
| Treatments, misc. experimental | 377 |
| U.S. government AIDS Web site | 386 |
| Vaccine Research Center, NIAID | 385 |
| Vaccine trial | 385 |
| Viread | 377 |
| Visa problems | 381 |
| Wan Yanhai released | 384 |
| Wan Yanhai | 383 |
| WTO trade rules | 386 |
021227
ATN38706
Copyright © 2002 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .